Sildenafil
| Evidence Level: L5 | Predicted Indications: 53 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Sildenafil |
| DrugBank ID | DB00203 |
| Brand Names (EU) | Mysildecard, Sildenafil ratiopharm, Vizarsin |
| Evidence Level | L5 |
| Predicted Indications | 53 |
| Top Prediction Score | 98.41% |
Approved Indication (EMA)
Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. In order for sildenafil to be effective, sexual stimulation is required.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | Ambras type hypertrichosis universalis congenita | 98.41% | DL |
| 2 | malformation syndrome with odontal and/or periodontal component | 98.23% | DL |
| 3 | syndrome with a Dandy-Walker malformation as major feature | 98.03% | DL |
| 4 | isolated genetic hair shaft abnormality | 97.86% | DL |
| 5 | hypertrichosis (disease) | 97.83% | DL |
| 6 | homozygous familial hypercholesterolemia | 93.77% | DL |
| 7 | hypoalphalipoproteinemia | 90.11% | DL |
| 8 | familial isolated trichomegaly | 79.78% | DL |
| 9 | genetic alopecia | 75.03% | DL |
| 10 | obsolete patella aplasia, coxa vara, and tarsal synostosis | 70.00% | DL |
| 11 | hypotrichosis simplex of the scalp | 69.88% | DL |
| 12 | pulmonary hypertension, primary, autosomal recessive | 69.19% | DL |
| 13 | familial clubfoot due to 17q23.1q23.2 microduplication | 68.83% | DL |
| 14 | kyphoscoliotic heart disease | 68.49% | DL |
| 15 | pulmonary hypertension | 68.06% | DL |
| 16 | migraine with brainstem aura | 67.69% | DL |
| 17 | chromosome 17q23.1-q23.2 deletion syndrome | 66.76% | DL |
| 18 | pulmonary arterial hypertension associated with congenital heart disease | 66.60% | DL |
| 19 | congenital hypotrichosis milia | 66.08% | DL |
| 20 | coxopodopatellar syndrome | 65.68% | DL |
Showing top 20 of 53 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.